Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Timothy Masterson MD, FACS

Timothy A. Masterson MD, FACS

Associate Professor, Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana

Dr. Masterson joined the faculty at the Indiana University Medical Center in Indianapolis, IN after earning his medical degree at Indiana University School of Medicine in 2001. He completed a general surgery internship and urology residency at University of Utah Health Sciences Center in Salt Lake City, followed by a fellowship in urologic oncology at Memorial-Sloan Kettering Cancer Center in New York City. He specializes in the treatment of adult genitourinary cancers and reconstruction. He is a board certified urologist and a fellow of the American College of Surgeons.

Dr. Masterson is an Associate Professor of Surgery in the Department of Urology at Indiana University School of Medicine, and has served as the department director for the Society of Urologic Oncology fellowship training program since 2013.

Disclosures

No disclosures reported.

Recent Contributions to PracticeUpdate:

  1. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Poor Outcomes in Men With Malignant Germ Cell Tumors
  2. Incidence of and Mortality Due to BCG Infections After BCG Instillation Therapy
  3. Risk Factors and Management of Patients With Testicular Seminoma With Discordant Elevated Serum Alpha-Fetoprotein
  4. Prostate-Only vs Whole-Pelvic Radiation Therapy in High-Risk and Very High–Risk Prostate Cancer
  5. Hypofractionated Post-Prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience
  6. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer
  7. Toxicity of Pelvic Lymph Node Irradiation With Intensity-Modulated Radiation Therapy for Prostate Cancer
  8. Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy
  9. Modified Retroperitoneal Lymph Node Dissection for Residual Tumor Post Chemotherapy

Recently Updated